Similar articles

• Re: Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer: M. L. Blute, Jr., T. J. Rushmer, F. Shi, B. J. Fuller, E. J. Abel, D. F. Jarrard and T. M. Downs J Urol 2015;194:1214-1219.

  Bhattar R, Priyadarshi S, Tomar V, Yadav SS, Vyas N, Agarwal N. Bhattar R, et al. J Urol. 2016 May;195(5):1623-1624. doi: 10.1016/j.juro.2015.12.091. Epub 2016 Feb 12. J Urol. 2016. PMID: 26876585 No abstract available.
• Re: Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer: M. L. Blute, Jr., T. J. Rushmer, F. Shi, B. J. Fuller, E. J. Abel, D. F. Jarrard and T. M. Downs J Urol 2015;194:1214-1219.

  Ozgur BC, Yuceturk CN. Ozgur BC, et al. J Urol. 2016 Sep;196(3):960-1. doi: 10.1016/j.juro.2016.03.184. Epub 2016 Jun 11. J Urol. 2016. PMID: 27294294 No abstract available.
• Vascular endothelial growth factor and bladder from a different perspective: not only an angiogenic factor.

  Burgu B, Aydogdu O. Burgu B, et al. J Pediatr Surg. 2010 Feb;45(2):447-52. doi: 10.1016/j.jpedsurg.2009.10.002. J Pediatr Surg. 2010. PMID: 20152373 Review.
• Re: DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers L. Mengual, M. Burset, E. Ars, J. J. Lozano, H. Villavicencio, M. J. Ribal And A. Alcaraz J Urol 2009; 182: 741-748.

  Pfister C, Lamy A, Gobet F, Frebourg T. Pfister C, et al. J Urol. 2010 Feb;183(2):825-7; author reply 827-8. doi: 10.1016/j.juro.2009.10.042. J Urol. 2010. PMID: 20034638 No abstract available.
• Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.

  Katz H, Wassie E, Alsharedi M. Katz H, et al. Med Oncol. 2017 Sep 1;34(10):170. doi: 10.1007/s12032-017-1029-8. Med Oncol. 2017. PMID: 28864844 Review.